Activated Charcoal Ammonium Carbonate Antimony Ars

證據等級: L5

預測適應症: 0 個

Multi-Component Archaic Compound: No Repurposing Indication Identified

One-Sentence Summary

This entry describes an 11-component mixture containing activated charcoal, arsenic trioxide, antimony derivatives, sulfuric acid, and lobelia inflata — a profile consistent with 19th-century pharmacopoeial or homeopathic preparations rather than a modern pharmaceutical entity. No regulatory approval exists in Taiwan, the compound lacks a DrugBank identifier, and the TxGNN model returned no predicted new indications, meaning this compound cannot proceed to a standard repurposing evaluation at this time. Without a resolvable single active ingredient, all downstream evidence scoring is unavailable.

Quick Overview

Item	Content
Original Indication	None on record
Predicted New Indication	None — TxGNN returned no result
TxGNN Prediction Score	N/A
Evidence Level	L5 — no actual studies; no model prediction returned
Taiwan Market Status	Not marketed (0 approvals)
Number of Licenses	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. The compound is a multi-ingredient mixture that does not correspond to any recognized single pharmaceutical entity in DrugBank or the TxGNN knowledge graph. The TxGNN model requires a resolvable DrugBank node to generate a repurposing score; because no DrugBank ID could be assigned to this mixture, no prediction was produced.

Several individual components do carry pharmacological history worth noting:

Activated charcoal — broad-spectrum gastrointestinal adsorbent, still used in acute poisoning management
Arsenic trioxide (As₂O₃) — the single component with a modern FDA-approved indication: acute promyelocytic leukemia (APL), marketed as Trisenox; however, approval is for a precisely formulated, standalone product, not as part of a mixture
Antimony potassium tartrate — 19th-century emetic and antiparasitic; now largely obsolete and classified as toxic
Lobelia inflata — historical respiratory stimulant containing lobeline, a nicotinic acetylcholine receptor partial agonist; not used in modern medicine
Ammonium carbonate / potassium carbonate — historical expectorants and antacids
Sulfuric acid, bromine, chlorine, tin — industrial or historical reagents with no recognized therapeutic role in combined oral preparations

As a combined formulation, the pharmacological interactions between these 11 components are undefined, and no published clinical data exists for the mixture as a whole.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Taiwan Market Information

This compound has no regulatory licenses on file in Taiwan. No approved indication, dosage form, or product name is available.

Authorization Number	Product Name	Dosage Form	Approved Indication
—	—	—	No records found

Safety Considerations

Important: Although structured safety data is unavailable for this mixture, several individual components carry significant known hazards that warrant explicit attention:

Arsenic trioxide — classified as a Group 1 human carcinogen (IARC); acute toxicity includes QTc prolongation, hepatotoxicity, and peripheral neuropathy

Antimony compounds (arsenate and potassium tartrate) — hepatotoxic and cardiotoxic; antimony trioxide is a possible human carcinogen (IARC Group 2B)

Sulfuric acid — severe corrosive; causes chemical burns to mucous membranes and the gastrointestinal tract

Bromine and chlorine — halogen oxidants; pulmonary and mucosal irritants at even low exposures

Tin — inorganic tin compounds have renal and neurological toxicity at elevated doses

Any future experimental use of this mixture would require a full preclinical toxicological characterization before any human administration can be considered.

Conclusion and Next Steps

Decision: Hold

Rationale: The compound cannot be evaluated for drug repurposing because it cannot be resolved to a single DrugBank entity, carries no regulatory standing in Taiwan, and the TxGNN model returned no predicted indications. Multiple component substances are inherently hazardous without therapeutic justification for their combined use.

To proceed, the following is needed:

Identify the intended active ingredient: Clarify whether this mixture corresponds to a named historical formulation (e.g., a 19th-century compound such as Fowler’s solution or a homeopathic preparation) and isolate the pharmacologically relevant component
Re-run with a single-entity input: If arsenic trioxide (As₂O₃) is the intended API, run a separate TxGNN query under DrugBank ID DB01169 (Arsenic trioxide / Trisenox) to obtain a legitimate repurposing prediction
Obtain MOA data: Query DrugBank API for the resolved single-entity API
Toxicological risk assessment: Commission a formal toxicology review of all 11 components and their interaction profile before any in vivo or clinical work
Regulatory pathway clarification: Determine whether any regulatory authority has evaluated this mixture and, if so, retrieve the original indication and safety dossier
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.